A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions. STS is a rare cancer that originates as an abnormal growth ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

Fragmented care - receiving medical treatment at more than one facility - has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...

WASHINGTON (Reuters) - GlaxoSmithKline's Votrient extended the lives of a significant number of patients suffering from an aggressive form of cancer without the disease getting worse, but the drug did ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...

Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic literature review of clinicopathologic characteristics of STSs in Latin American ...

Fragmented care — receiving medical treatment at more than one facility — has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...

Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...